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ABSTRACT
Introduction: Many devices (e.g., nebulizers
and spacers) are used to deliver aerosol in a
non-invasive ventilation circuit (NIV) without
any special recommendation. The aim of the
present work was to compare the doses
delivered from seven different aerosol delivery
systems when placed in the NIV using
automatic continuous positive airway pressure
(Auto-CPAP).
Methods: Three spacers and three vibrating
mesh nebulizers were compared to a Sidestream
jet nebulizer (SIDE). Each device was placed
proximal to a breathing simulator in a standard
NIV circuit with a 500 ml tidal volume,
15 breaths/min and a 1:3 inspiratory-expiratory
ratio. Two ml of salbutamol solution containing
10,000 lg was nebulized using Aerogen Pro
(PRO), Aerogen Solo (SOLO), NIVO and SIDE.
Twelve metered dose inhaler doses, containing
100 lg salbutamol each, were delivered using
AeroChamber MV (AC), AeroChamber Vent (VC)
and AeroChamber Mini (MC). Total emitted dose
(TED) and its percentage were determined.
Aerodynamic droplet characteristics were
measured using cooled Andersen Cascade
Impactor.
Results: The vibrating mesh nebulizers used
had significantly more (p\0.001) TED
compared to the jet nebulizer. The spacers
used had higher TED % (p\0.001) compared
to the nebulizers. The fine particle fraction of
SIDE was the highest (p = 0.021) and mass
median aerodynamic diameter of the spacers
was the smallest (p = 0.001). The fine particle
dose from vibrating mesh nebulizers was the
greatest (p = 0.02).
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Conclusions: Aerosol delivery in Auto-CPAP
NIV is feasible; however, aerosol delivery
method should be chosen or substituted with
care. 2 mg delivered from a spacer would be
equivalent to 3 mg nebulized from a vibrating
mesh nebulizer and 5 mg nebulized from a
Sidestream.
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INTRODUCTION
Aerosols are commonly used with mechanically
ventilated patients [1, 2]. They are delivered by
a metered dose inhaler (MDI) with or without
spacer modification to be used in ventilator
circuits or by nebulizers [1, 2]. Previous studies
using patients with stable asthma [3] and COPD
[4] confirmed that aerosol delivery in bilevel
positive airway pressure (BiPAP) non-invasive
ventilation circuit (NIV) is feasible and can be
effective. Many studies had compared the use of
different nebulizers [2, 4–9] and different
spacers [10–15] in the BiPAP NIV circuit.
However, few studies have compared different
nebulizers and MDI with spacers in the same
study or the practicability of aerosol delivery in
a continuous positive airway pressure (CPAP)
NIV circuit. CPAP applies a pre-set pressure level
on a continuous basis. CPAP devices apply
continuous positive airway pressure
throughout the breathing cycle. Thus, the
ventilator itself does not cycle during CPAP,
no additional pressure above the level of CPAP
is provided, and patients initiate all of their
breaths. On the other hand, an Automatic
Continuous Positive Airway Pressure ventilator
(Auto-CPAP) automatically titrates the amount
of pressure delivered to the patient on a
breath-by-breath basis by measuring the
resistance in the subject’s breathing, changing
its level over time [16, 17]. Some ventilators
include more modalities of ventilation
including CPAP and Auto-CPAP.
Additionally, jet nebulizers should ideally be
replaced by inhalers which do not distribute
aerosol into the environment, e.g., MDI spacers
or valve holding chambers when treating
patients with, for example, Middle East
respiratory syndrome [18].
The European Respiratory Society Guidelines
on the use of nebulizers [19] recommend the
determination of the aerodynamic
characteristics of the droplets in the emitted
dose. However, it had been reported that the
Comite´-Europe´en-Normalisation (2001) (CEN)
method to measure the aerodynamic
characteristics, proposed by the Guidelines
[19], should not be used due to the effects of
evaporation. Instead the use of a cooled Next
Generation Impactor is recommended [20]. The
Anderson Cascade Impactor (ACI) was also
validated to measure the aerodynamic
characterization of the dose delivered by
nebulizers [21]. Only the CEN method that
identifies the fate of the nebulized dose using
sinus flow breath simulation, and filters to
entrain the inhalation and exhalation output
of a nebulized, dose should be used.
The aim of the present work was to identify
equivalent doses for COPD Auto-CPAP NIV
patients due to the reported differences in
output and performance between different
nebulizers [20, 22] and different spacers [1,
23]. This article does not contain any new
studies with human or animal subjects
performed by any of the authors.
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METHODS
Delivery Systems
A 10,000 lg (in 2 ml) salbutamol respiratory
solution (Farcolin respirator solution,
5000 lg ml-1; Pharco Pharmaceuticals,
Alexandria, Egypt) was nebulised using the
Aerogen Pro [PRO] Nebuliser and Aerogen
Solo [SOLO] Nebuliser (Aerogen Limited,
Galway, Ireland), NIVOTM Nebuliser (Aerogen/
Philips, Andover, MA, USA) and the Sidestream
[SIDE] nebuliser (Philips, Andover, MA, USA)
attached to a PortaNeb compressor (Philips
Respironics, UK). The PortaNeb compressor
provides an air flow of 6 l min-1 into the
nebuliser to aerosolize the liquid. Twelve MDI
doses containing 100 lg salbutamol (Ventoline,
GlaxoSmithKline, Cairo, Egypt) each were
delivered using AeroChamber MV [AC],
AeroChamber Vent [VC] and AeroChamber
Mini [MC] spacers (Trudell Medical
International, London, Canada).
The choice of salbutamol dosage for different
devices was in accordance with the previous
literatures [1, 20, 22–25].
In-Vitro Fate of the Aerosolized Dose Using
an Automatic Continuous Positive Airway
Pressure (Auto-CPAP) System Used for NIV
Each of the seven aerosol delivery methods
(previously described) were assembled
according to Fig. 1 which was designed to
mimic that of a patient receiving NIV [5].
A breathing simulation machine (model
5600i, Grand Rapids, USA) was connected to
an Auto-CPAP (3B Medical, Lake Wales, USA)
(Fig. 1). The NIV breathing circuit consisted of a
180 cm length of corrugated tubing (diameter of
22 mm) and a fixed leak expiration port (B&D
Electromedical, Warwickshire, UK).
Spontaneous breathing was simulated to
provide a tidal volume of 500 ml with a rate of
15 breaths per minute and inspiratory to
expiratory phase ratio of 1:3. The breathing
simulator setting was chosen to mimic the
breathing pattern of COPD patients when
non-invasive support ventilation was
prescribed during acute exacerbations at local
hospitals. The outlet of each nebulizer was
attached to its standard T-piece and both
outlets were connected into the NIV circuit
tubing with a tight seal. In addition, each spacer
was placed into the NIV circuit and both outlets
were connected to the NIV circuit tubing with a
tight seal.
An electrostatic filter pad enclosed in a filter
holder (Pari GmbH, Starnberg, Germany) was
attached next to the breathing machine
(inhalation filter). This filter would entrain all
the aerosol produced during the inhalation
period of a breathing cycle and thus provides a
good measure of the total inhaled aerosol dose
(the in vitro total emitted dose available for
inhalation). Another electrostatic filter was
attached next to the Auto-CPAP (ventilator
filter) to check if any aerosol reaches the
ventilator. A third electrostatic filter was
placed 4 cm above the outlet of the expiration
port of the NIV system (expiration filter). A
vacuum of 25 l min-1 was drawn through this
filter to ensure that it captured the entire dose
that was expelled out of the NIV system [5].
The nebulizer position within the ventilator
circuit was proximal to the breathing simulator
with the expiration port positioned after it
towards the ventilator [5]. The Auto-CPAP was
switched on until it reached a pressure of 7 cm
H2O (about 10 min), then the breathing
machine was switched on 30 s before
delivering the aerosol. Salbutamol solution,
10,000 lg in 2 ml, was nebulized to sputtering
for the SIDE and to dryness for PRO, SOLO and
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NIVO. Twelve MDI doses containing 100 lg
salbutamol each were delivered using AC, VC
and MC. Each dose of the 12 MDI doses was
actuated at the start of the inspiratory phase of
the breathing cycle.
For each aerosol delivery method five
determinations were made (n = 5). The
amounts of salbutamol entrained on each
filter, left in the nebulizer chamber and
deposited inside the tubing or the spacer used
were recovered by rinsing with 90%
acetonitrile. Amounts entrained on the filter
were sonicated with 90% acetonitrile
prior to rinsing. High-performance liquid
chromatography (HPLC) with UV detection
was used to identify amounts of salbutamol.
The method used a 25 mm 9 4.6 mm ZORBAX
Eclipse Plus C18, ODS1 column (Agilant, Santa
Clara, USA) through which a mobile phase
consisted of a mixture of acetonitrile and
water [containing 0.1% phosphoric acid]
(90:10, v/v) was pumped at 1 ml min-1 using
Agilent 1260 Infinity preparative pump
(G1361A), Agilent 1260 Infinity Diode array
detector VL (G131SD) was set at 225 nm with an
injection volume 100 ll. Calibration solutions
ranged from 4 to 100 lg ml-1 (w/v). The limit of
detection was 0.35 lg ml-1 and the lower limit
of quantification was 2.55 lg ml-1.
The Aerodynamic Particle Size
Characterization Using the ACI
An Anderson Cascade Impactor [ACI] (Copley
Scientific Ltd, Nottingham, UK) was used to
determine the particle droplet size distribution
of the aerosolized drug that would be delivered
to the patient. The experimental set-up is
described in Fig. 2. This Figure shows that the
ACI was always proximal to the breathing
simulator to collect and measure aerosol that
was going to the inhalation filter. The position
of each aerosol delivery method was proximal
to the ACI.
The ACI, with its plates in situ, was placed in
a refrigerator at 5 C for 60 min before use [21].
Hence, the induction port of the ACI was
connected directly into the NIV circuit with
an air-tight seal. The vacuum flow through the
ACI apparatus was provided by a vacuum pump
(Brook Crompton, Huddersfield, UK). The flow
rate was measured using an electronic digital
flow meter (MKS Instruments, Andover, USA).
For each aerosol delivery method three
determinations were made (n = 3). The time
to start the Auto-CPAP and breathing machine
and the doses delivered by the nebulizers and
the spacers as described in the previous
section.
Fig. 1 Schematic design of the in vitro non-invasive ventilation circuit method to determine the fate of the aerosolized dose
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Salbutamol deposited on each plate of the
ACI, nebulization chamber, spacer and tubing
was recovered by rinsing with 90%
acetonitrile. Similarly, the mass entrained on
the filters was recovered by sonication and
rinsing. HPLC used as described in the
previous section.
The fine particle dose (FPD), fine particle
fraction (FPF %) and the mass median
aerodynamic diameter (MMAD) was
determined using Copley Inhaler Testing Data
Analysis Software (CITDAS, Copley Scientific,
Nottingham, UK) impactor data analysis
software.
Statistical Analysis
All data are expressed as mean (SD). One-way
analysis of variance (ANOVA) with the
application of least significant difference
correction was used to compare the seven
different aerosol delivery methods with SPSS
V17.0 (SPSS Inc., Chicago, USA).
RESULTS
Table 1 provides a summary of the fate of the
delivered dose. No salbutamol was recovered
from the ventilation filter or the tubing between
this filter and the expiration port. No
salbutamol was recovered from the expiration
port filter when using any of the spacers to
deliver the inhaled dose. Statistical analysis
revealed that there was a significant (p\0.001)
difference in the amounts recovered on the
inhalation filters (Total emitted dose) between
the seven methods. Similarly there were
significant differences (p\0.001) for the
residual volumes and the amount deposited in
the T-piece and the amount deposited on the
spacer. For the three vibrating mesh nebulizers
used there was significantly more (p\0.001)
salbutamol entrained on the inhalation filter
compared to the jet nebulizer. In addition, the
amounts deposited on the tubing and
expiration port were significantly greater
(p\0.001) for the three vibrating mesh
nebulizers, but amounts left in the nebulizer
was significantly greater (p\0.001) for SIDE.
As shown in Table 1, we used percentage to
compare the nebulizers to the spacers. The three
spacers used had higher percentages of
salbutamol deposited on the inhalation filter
(p\0.001) compared to the nebulizers. In
addition, the percentages of salbutamol
entrained in the spacer were higher than those
Fig. 2 Schematic design of the methodology to measure the aerodynamic characteristics of the aerosolized dose with the
non-invasive ventilation circuit. ACI Anderson Cascade Impactor
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in the nebulization chambers (p\0.001).
However, the percentages of salbutamol
deposited on the tubing and the exhalation
port filter were higher for the nebulizers
(p\0.001). No significant difference between
the three vibrating mesh nebulizers as well as
between all the three spacers in all parameters.
The aerodynamic droplet size distribution
from each aerosol delivery method is shown in
Fig. 3 with a summary in Table 2. Consistent
with the above results no drug was recovered
on the ventilation filter or deposited in the
tubing of the NIV circuit between the
expiration port and ventilator. In addition,
no salbutamol was recovered from the
expiration port filter when using any of the
spacers to deliver the inhaled dose. The FPF of
SIDE was the highest (p = 0.021), MMAD of the
AC and MC spacers was the smallest
(p = 0.001) and the FPD from the SOLO
nebulizer was the greatest (p\0.02).
The NIVO had relatively smaller FPF and FPD
compared to the other two vibrating mesh
nebulizers, but there was no significant
difference.
All of the spacers used had a smaller MMAD
(p = 0.001) and relatively higher FPF, but not
significant, compared to the three vibrating
mesh nebulizers used. The VC resulted in
aerosol with relatively higher MMAD and
lower FPF than the AC and the MC, but was
not significant.
DISCUSSION
Placing either the Aerogen Pro, as a vibrating
mesh nebulizer, or the Sidestream, as a jet
nebulizer between expiration port and
breathing simulator was previously proven to
produce a higher delivery of the drug to the
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expiration port [5, 7]. Hence, we placed the
seven used inhalation devices in the above
position. The Auto-CPAP added positive
pressure which will direct air towards the
patient through the inspiratory phase.
Therefore, the entire aerosolized dose in the
inspiratory phase is aimed at the inhalation
filter. During expiratory phase more aerosols
would exit from the expiration port. However,
during an expiratory phase, Auto-CPAP keeps
up positive pressure hence; patient’s airways do
not collapse when they breathe out. This
positive pressure allows exhaled air to leave
the expiration port so that the patient inhales
fresh air. However, the positive pressure is
adequate to avoid the total escape of the dose
nebulized during the expiratory phase. Hence,
some aerosols are held within the NIV circuit [5,
7]. Deposition due to gravity in expiration
phase is not significant because of the droplet
small size and the very limited time for the
expiratory phase, which would be 3 s as
mentioned before in the methodology (1: 3
inspiratory to expiratory ration). When the
inspiratory phase starts the aerosol kept in the
NIV circuit, nebulized during the expiratory
phase, was directed towards the breathing
simulator (hence patient).
The holding effect of the nebulized aerosol
within the NIV tubing in the expiratory phase
was similar to that when an MDI was used with
a spacer, hence might enhance evaporation and
therefore decreases droplets size [5, 7].
The MMAD for the Aerogen Pro and
Sidestream were 4.5 and 3.9 lm, respectively,
which is comparable to our previous study
using a BiPAP NIV circuit [5]. However, in an
earlier study using the same method and
nebulizer without the NIV, MMADs were 5.0
and 4.2 lm [20] respectively. In addition FPF in
the NIV circuit was higher. Similar to other
previous studies [26] these variations show that
evaporation could really occur in the NIV
circuit. This suggests that aerosol delivery to
the lungs of NIV patients would be better than
when a patient uses the conventional
nebulization method [5]. In addition, it is
advisable to remove the humidifier (which
might increase the droplet size by
condensation), that many patients using CPAP
Fig. 3 The mean
(SD) aerodynamic dis-




ods using the Ander-
son Cascade Impactor
methodology (n = 3)
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are utilizing, when a bronchodilator is
administered [17].
No salbutamol was found on the ventilator
filter or tubing between this filter and the
expiration port. This was due to the 840 ml
inner volume of the NIV tubing and the 500 ml
tidal volume together with the Auto-CPAP
positive pressure through the expiratory phase
[5].
The results of the three tested vibrating mesh
nebulizers were comparable in all the
parameters. Although Sidestream MMAD was
smaller and FPF was greater than all tested
vibrating mesh nebulizers, there is likely little
clinical significance because the difference is
small, especially when compared to SOLO.
However, an average of 1.5-fold greater FPD of
vibrating mesh nebulizers, compared to the
Sidestream, would supply greater lung
deposition and likely be of clinical significance.
This great difference is due to the smaller residual
volume in all vibrating mesh nebulizers used [5,
27, 28]. Although pulmonary clinical response
whenusing any of the tested inhalationmethods
might be at the top of the dose response
relationship, the critical clinical effect would be
from larger systemic absorption of the vibrating
mesh nebulizers if we did not change the dose.
These results suggest that approximately 2 mg
nebulized from any of the tested vibrating mesh
nebulizers would be equivalent to 3 mg
nebulized from a Sidestream. This difference
between vibrating mesh nebulizers and jet
nebulizers in the Auto-CPAP NIV circuit is
similar to those reported in the BiPAP NIV
circuit [4, 5, 29, 30] and highlights the need to
use a lower dose when switching a patient to a
vibrating mesh nebulizer. These results also
highlight the feasibility of aerosol delivery in
the Auto-CPAP NIV circuit.
However, when using any of the tested






















































































































































































122 Pulm Ther (2016) 2:115–126
the aerosol on the tubing of the NIV was about
threefold that of the jet nebulizer [5, 28]. This
could result in wasting a high percentage of the
nebulized dose in the tubing. This was due to
the downward aerosolization of the vibrating
mesh nebulizers compared to the upward
aerosolization of the jet nebulizer which
results in the return of any condensate to the
jet nebulizer chamber [5, 28].
The results of the three tested spacers were
comparable in all the parameters. The spacers
used showed no significant deposition on the
expiration port filter at all. This could be
attributed to the release of all the MDI
delivered doses in the spacers at the start of
the inspiratory phase allowing the entire
delivered dose to be directed to the patient
[31]. The TED deposited on the inhalation filter
of the spacers used was about one-fifth and
one-third of that of the vibrating mesh
nebulizer and the jet nebulizer, respectively.
However, the nominal dose placed into the
nebulizer was about seven times that placed in
the spacer. This resulted in an average TED %
from the spacer that was 1.5-fold that of the
vibrating mesh nebulizers and 2.5-fold that of
the jet nebulizer. These results suggest that
approximately 2 mg delivered from a spacer
would be equivalent to 3 mg nebulized from a
vibrating mesh nebulizer and 5 mg nebulized
from a Sidestream. Ari et al. [25] in the BiPAP
NIV circuit; showed that the delivery efficiency
with the MDI was threefold greater than with
the jet nebulizer (p = 0.002).
In addition, about 50% of the delivered dose
was deposited on the wall of the spacers tested.
It is well known that particles deposited in the
spacer have a very large aerodynamic particle
size that would not reach the lung and could
cause adverse effect. Hence, spacers could
decrease the unwanted adverse effect when
used to deliver aerosol in the NIV circuit
compared to the nebulizer. In addition, all the
spacers tested resulted in very small MMADs
compared to all the nebulizers tested. This
suggests that evaporation effects were more
prominent due to the longer distance of the
actuated dose in the spacer to the ACI, resulting
in further evaporation. The large amount of
drug with large particle size deposited on the
wall of the spacer, the better TED % and the
smaller MMAD from the spacers used could
suggest better lung deposition with lower dose
and lower side effect when using a spacer in a
NIV.
A study by Power et al. [27] showed a
superiority of the NIVO vibrating mesh
nebulizer over the jet nebulizer and the MDI
in the percentage of the aerosol delivered to the
patient when placed in the NIV [27]. Power
et al. did not state when they actuated the dose
(Perhaps during the expiratory phase). In
addition, they did not use a spacer which
might improve their MDI results. An
additional variable could be the types of
salbutamol used in the study as it is known
that different types of salbutamol have variable
aerosol characteristics [32]. Hence, this may add
some variation to the results provided from the
MDI with spacers and nebulizers.
The seven tested inhalation device are often
used in similar clinical conditions. However,
according to our results, to deliver 2 mg (20
doses) efficiently by the spacer to the NIV
patient, health care providers need to stand
for more than 1 min (about 80 s), as they have
to adjust the actuation of each dose at the start
of the inspiratory phase. Hence, they need to be
focused when delivering 2 mg by a spacer to
result in a comparable lung deposition of 3 mg
aerosolized by a vibrating mesh nebulizer or
5 mg by a jet nebulizer, which only requires a
press of a button to start delivering the dose.
Hence, using spacers might be considered time
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consuming to the health care provider. This,
together with the significant differences in the
aerodynamic properties of the delivered dose
from the jet nebulizers, vibrating mesh
nebulizers and spacers tested in a NIV circuit,
highlights why preliminary in vitro data is
required for all inhalation delivery methods
before introduction in the NIV.
CONCLUSIONS
Aerosol delivery during Auto-CPAP NIV is
practical and would be of clinical benefit to
patients. Whilst the aerodynamic characteristics
of the jet nebulizer were slightly more
encouraging for lung deposition, there was a
much larger FPD from the vibrating mesh
nebulizers due to their smaller residual
volume. The spacers had a higher TED %,
lower MMAD compared to all the tested
nebulizers. The in vitro results imply that 2 mg
drug delivered from a spacer, which may be
more time consuming for the health care
provider, would be equivalent to 3 mg
nebulized from a vibrating mesh nebulizer and
5 mg nebulized from a Sidestream jet nebulizer.
The extent of this difference suggests that;
although the proper dosage of salbutamol is
often based on the desired clinical effect; the
need to find out in vitro data for all inhalation
delivery methods before substitution or
introduction into the NIV circuit is also very
important.
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